A Phase 2/3, Randomized, Open-label Study to Compare the Efficacy and Safety of Lenalidomide (Revlimid) Versus Investigator's Choice in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma.

Trial Profile

A Phase 2/3, Randomized, Open-label Study to Compare the Efficacy and Safety of Lenalidomide (Revlimid) Versus Investigator's Choice in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma.

Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 30 May 2018

At a glance

  • Drugs Lenalidomide (Primary) ; Etoposide; Gemcitabine; Oxaliplatin; Rituximab
  • Indications Diffuse large B cell lymphoma
  • Focus Registrational; Therapeutic Use
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 27 May 2018 This trial has been completed in France (End date: 2018-04-05)
    • 09 May 2018 This trial has been completed in Sweden (End date: 2018-04-05)
    • 18 Apr 2018 This trial has been completed in Spain (End date: 2018-04-05)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top